Ultragenyx Exceeds 2025 Revenue Guidance, Reports Strong Cash, and Highlights Key 2026 Pipeline Catalysts
RARE sits 27% above its 52-week low of $18.41.
Summary
Ultragenyx Pharmaceutical reported preliminary 2025 revenues exceeding guidance, a robust year-end cash position, and detailed multiple significant clinical and regulatory milestones anticipated for 2026.
Key Events · Earnings and Guidance · RARE
-
Preliminary 2025 Revenue Exceeds Guidance
Ultragenyx reported preliminary unaudited total revenue for fiscal year 2025 between $672 million and $674 million, surpassing the top end of its previous guidance range. Crysvita® revenue also exceeded guidance, while Dojolvi® revenue met the midpoint of its range.
-
Strong Year-End Cash Position
The company ended 2025 with approximately $735 million in cash and investments, providing a solid financial foundation for its operations and pipeline advancements.
-
Key 2026 Regulatory Milestones Anticipated
Ultragenyx expects a PDUFA date in Q3 2026 for DTX401 (GSDIa) and is on track for an early 2026 BLA resubmission for UX111 (MPS IIIA), representing two potential gene therapy approvals.
-
Pivotal Phase 3 Data for Angelman Syndrome Expected
Data from the fully enrolled, pivotal Phase 3 Aspire study of GTX-102 for Angelman syndrome is anticipated in the second half of 2026, a significant event for the pipeline.
Analysis · RARE · Life Sciences
Ultragenyx Pharmaceutical reported preliminary 2025 revenues that surpassed its guidance, indicating strong commercial performance for its key products. The substantial year-end cash and investments position provides significant financial flexibility and runway for ongoing operations and pipeline development. The outlined 2026 clinical and regulatory catalysts, including two potential gene therapy approvals and pivotal Phase 3 data, are critical value drivers that could significantly de-risk the pipeline and fuel future growth, setting a positive outlook for the company's operational and clinical progress.
At the time of this filing, RARE was trading at $23.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $18.41 to $46.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.